Literature DB >> 3044343

A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection.

B Knapp1, A Shaw, E Hundt, B Enders, H A Küpper.   

Abstract

We have isolated a cDNA clone coding for 165 amino acids of a histidine alanine rich protein. An extended repeat region of this clone codes for the tripeptide Ala-His-His, which is extremely conserved, and for the tripeptide Ala-Ala-Asp, which shows only slight variability among the repeat units. This antigen exhibits high homology to the HRPII antigen described by Wellems and Howard (1986). The coding region was expressed in E. coli as a MS2-polymerase fusion protein, which was purified and used for immunization of Aotus monkeys. The animals immunized with this fusion protein showed only low parasitemias (less than 2%) after infection with P. falciparum, while animals from the control group or animals immunized with a MS2-fusion protein carrying other malaria specific sequences were not protected. The result suggests that this antigen is a good candidate for a malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044343

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  12 in total

Review 1.  Structure and possible function of Plasmodium falciparum proteins exported to the erythrocyte membrane.

Authors:  B Knapp; E Hundt; K R Lingelbach
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

2.  Cloning and characterization of chromosome breakpoints of Plasmodium falciparum: breakage and new telomere formation occurs frequently and randomly in subtelomeric genes.

Authors:  A Scherf; D Mattei
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

3.  Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins.

Authors:  B Knapp; E Hundt; B Enders; H A Küpper
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Interaction of Plasmodium falciparum histidine-rich protein II with human lymphocytes leads to suppression of proliferation, IFN-gamma release, and CD69 expression.

Authors:  Padmalaya Das; Jasvir S Grewal; Virander S Chauhan
Journal:  Parasitol Res       Date:  2006-06-21       Impact factor: 2.289

5.  Antimalarial activity of new floxacrine-related acridinedione derivatives: studies on blood schizontocidal action of potential candidates against P. berghei in mice and P. falciparum in vivo and in vitro.

Authors:  W Raether; B Enders; J Hofmann; U Schwannecke; H Seidenath; H Hänel; M Uphoff
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

6.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

7.  Identification of Plasmodium falciparum histidine-rich protein 2 in the plasma of humans with malaria.

Authors:  M E Parra; C B Evans; D W Taylor
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

8.  Conservation of antigen components from two recombinant hybrid proteins protective against malaria.

Authors:  B Knapp; U Nau; E Hundt
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

9.  Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Authors:  B U von Specht; B Knapp; G Muth; M Bröker; K D Hungerer; K D Diehl; K Massarrat; A Seemann; H Domdey
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Authors:  S P Chang; S E Case; W L Gosnell; A Hashimoto; K J Kramer; L Q Tam; C Q Hashiro; C M Nikaido; H L Gibson; C T Lee-Ng; P J Barr; B T Yokota; G S Hut
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.